Evidence map›Paper›PMID 28605509›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2017

A novel homozygous UMOD mutation reveals gene dosage effects on uromodulin processing and urinary excretion.

Noel Edwards, Eric Olinger, Jennifer Adam, Michael Kelly, Guglielmo Schiano, Simon A Ramsbottom, Richard Sandford, Olivier Devuyst, John A Sayer

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  7. Review
  8. Review
  9. Article
  10. The Use of Genomics to Drive Kidney Disease Drug Discovery and Development.Clinical journal of the American Society of Nephrology : CJASN · 2020
    Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Noel EdwardsInstitute for Cell and Molecular Biosciences, Newcastle University Medical School, Newcastle upon Tyne, UK.
Eric OlingerInstitute of Physiology, University of Zurich, CH-8057 Zurich, Switzerland.
Jennifer AdamRenal Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Michael KellyRenal Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Guglielmo SchianoInstitute of Physiology, University of Zurich, CH-8057 Zurich, Switzerland.
Simon A RamsbottomInstitute for Cell and Molecular Biosciences, Newcastle University Medical School, Newcastle upon Tyne, UK.
Richard SandfordAcademic Department of Medical Genetics, Cambridge Biomedical Campus, Cambridge, UK.
Olivier DevuystInstitute of Physiology, University of Zurich, CH-8057 Zurich, Switzerland.
John A SayerRenal Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Newcastle University · GBUniversity of Zurich · CHNewcastle upon Tyne Hospitals NHS Foundation Trust · GB

Funding

Medical Research Council MR/M012212/1
6 · The paper itself

Abstract

Heterozygous mutations in UMOD encoding the urinary protein uromodulin are the most common genetic cause of autosomal dominant tubulointerstitial kidney disease (ADTKD). We describe the exceptional case of a patient from a consanguineous family carrying a novel homozygous UMOD mutation (p.C120Y) affecting a conserved cysteine residue within the EGF-like domain III of uromodulin. Comparison of heterozygote and homozygote mutation carriers revealed a gene dosage effect with unprecedented low levels of uromodulin and aberrant uromodulin fragments in the urine of the homozygote proband. Despite an amplified biological effect of the homozygote mutation, the proband did not show a strikingly more severe clinical evolution nor was the near absence of urinary uromodulin associated with urinary tract infections or kidney stones.

Indexed as

Gene DosageMutationAdolescentAdultAgedAge of OnsetFemaleHeterozygoteHomozygoteHumansKidney DiseasesMaleMiddle AgedPedigreeUromodulinYoung AdultUMOD protein, humanUromodulingouthomozygous mutationTamm-Horsfall proteintubulointerstitial kidney diseaseuromodulin

Identifiers

PMID28605509
PMCPMC5837645
OpenAlexW2622889868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.